The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia

The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia

ABSTRACTThrombocytopenia is one of the most common hematological adverse reactions in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKI) therapy, causing life-threatening bleeding cases. However, there are fewer therapeutic drugs for TKI-induced thrombocytopenia. Eltr...

Full description

Bibliographic Details
Main Authors: Li Liu, Yilin Chen, Yan Liang, Li Meng, Jingming Guo, Chuancai Liu, Zhe Zhao, Jing Zou, Wenjuan He, Jiangzhao Zhang, Zhenya Hong, Caixia Liang, Xianjie Fu, Hui Wu, Youshan Zhang, Yanli Zhang, Weiming Li
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Hematology
Subjects:
Chronic Myeloid Leukemia
eltrombopag
thrombocytopenia
tyrosine kinase inhibitors
efficacy
safety
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2248434

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2023.2248434

Similar Items